发明名称 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
摘要 The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
申请公布号 US9139654(B2) 申请公布日期 2015.09.22
申请号 US201012977843 申请日期 2010.12.23
申请人 Roche GlyeArt AG 发明人 Umaña Pablo;Jean-Mairet Joël;Bailey James E.
分类号 C07K16/00;C07K16/28;C07K16/30;C12P21/00 主分类号 C07K16/00
代理机构 Sterne, Kessler, Goldstein & Fox P.L.L.C. 代理人 Sterne, Kessler, Goldstein & Fox P.L.L.C. ;Shea, Jr. Timothy J.
主权项 1. A glycoengineered, recombinant antibody comprising an IgG Fc region containing N-linked oligosaccharides, wherein said antibody is isolated from a Chinese Hamster Ovary host cell and has been engineered to have an increased ratio of GlcNAc residues to fucose residues in the Fc region compared to a corresponding antibody produced by a Chinese Hamster Ovary host cell that has not been glycoengineered, and wherein said antibody has increased Fc-mediated cellular cytotoxicity as a result of said glycoengineering.
地址 CH